cb-839
Small moleculeexperimental
Clinical trial activity
18 trials · 10 clinical orgs · 0 marketing orgs
Phase 1
14
Phase 2
10
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2014 (NCT02071862)
Timeline
Indications
Studied for
- Astrocytoma · Phase 1
- Bone Marrow Cells · Phase 1/Phase 2
- Brain Neoplasms · Phase 1
- Breast Neoplasms · Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 1/Phase 2
- Carcinoma, Renal Cell · Phase 2
- Colonic Neoplasms · Phase 1/Phase 2
- Colorectal Neoplasms · Phase 1/Phase 2
- Healthy Volunteers · Phase 1
- Intestinal Neoplasms · Phase 1
- Leukemia · Phase 1/Phase 2
- Leukemia, Lymphocytic, Chronic, B-Cell · Phase 1
- Leukemia, Myeloid, Acute · Phase 1/Phase 2
- Leukemia, Myelomonocytic, Chronic · Phase 1/Phase 2
- Lung Neoplasms · Phase 1/Phase 2
- Lymphoma, Non-Hodgkin · Phase 1
- Melanoma · Phase 1/Phase 2
- Meningeal Neoplasms · Phase 1
- Mesothelioma · Phase 1
- Multiple Myeloma · Phase 1
- Mutation · Phase 2
- Myelodysplastic Syndromes · Phase 1/Phase 2
- Neoplasms · Phase 2
- Ovarian Neoplasms · Phase 1
- Rectal Neoplasms · Phase 1/Phase 2
- Risk Factors · Phase 1/Phase 2
- Triple Negative Breast Neoplasms · Phase 2
- Waldenstrom Macroglobulinemia · Phase 1
Mechanism of action
GLS inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- cb-839
- cb-839
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04250545 | Phase 1 | Mar 13, 2020 | City of Hope National Medical Center, National Cancer Institute (NCI) |
| NCT03872427 | Phase 2 | Oct 10, 2019 | National Cancer Institute (NCI), University of Texas at Houston |
| NCT03944902 | Phase 1 | Jul 31, 2019 | University of Alabama, Birmingham |
| NCT03831932 | Phase 1/Phase 2 (Phase 2) | May 2, 2019 | National Cancer Institute (NCI), Ohio State University |
| NCT03875313 | Phase 1/Phase 2 (Phase 2) | Mar 31, 2019 | Calithera Biosciences |
| NCT03528642 | Phase 1 | Feb 8, 2019 | Mayo Clinic, National Cancer Institute (NCI) |
| NCT03798678 | Phase 1 | Dec 26, 2018 | Mayo Clinic, National Cancer Institute (NCI) |
| NCT03428217 | Phase 2 | Mar 27, 2018 | Calithera Biosciences |
| NCT03263429 | Phase 1/Phase 2 (Phase 2) | Aug 23, 2017 | Calithera Biosciences, National Cancer Institute (NCI), Vanderbilt University |
| NCT03163667 | Phase 2 | Jul 1, 2017 | Calithera Biosciences |
| NCT03047993 | Phase 1/Phase 2 (Phase 2) | Jun 1, 2017 | Calithera Biosciences, National Cancer Institute (NCI), University of Texas at Houston |
| NCT03057600 | Phase 2 | May 1, 2017 | Calithera Biosciences |
| NCT02944435 | Phase 1 | Oct 1, 2016 | Algorithme Pharma Inc, Calithera Biosciences |
| NCT02861300 | Phase 1/Phase 2 (Phase 2) | Aug 1, 2016 | Case Western Reserve University |
| NCT02771626 | Phase 1/Phase 2 (Phase 2) | Aug 1, 2016 | Calithera Biosciences |
| NCT02071927 | Phase 1 | Mar 1, 2014 | Calithera Biosciences |
| NCT02071888 | Phase 1 | Feb 1, 2014 | Calithera Biosciences |
| NCT02071862 | Phase 1 | Feb 1, 2014 | Calithera Biosciences |
Showing 18 of 18 trials
Page 1 / 1
Organizations
Research & Development (10)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Calithera Biosciences | For profit | 11 | 9 | 2 | 2014 |
| National Cancer Institute (NCI) | Government | 7 | 5 | 2 | 2017 |
| Mayo Clinic | Academic/Hospital | 2 | 0 | 1 | 2018 |
| University of Texas at Houston | Academic/Hospital | 2 | 1 | 1 | 2017 |
| Algorithme Pharma Inc | For profit | 1 | 0 | 1 | 2016 |
| Case Western Reserve University | Academic/Hospital | 1 | 1 | 1 | 2016 |
| City of Hope National Medical Center | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Ohio State University | Academic/Hospital | 1 | 0 | 1 | 2019 |
| University of Alabama, Birmingham | Academic/Hospital | 1 | 1 | 1 | 2019 |
| Vanderbilt University | Academic/Hospital | 1 | 1 | 1 | 2017 |
10 organizations
Page 1 / 1